Cardinal Health is targeting more than $50 billion in specialty revenues by fiscal 2026, banking on robust growth in pharmaceuticals and specialty drugs. This ambitious outlook comes as the company navigates recent challenges, including a $184 million goodwill impairment and a 10.7% drop in stock price year-to-date. Despite these hurdles, analysts have given Cardinal Health a positive Zacks Rank of #2 (Buy), suggesting it remains undervalued and offers significant upside potential. The company's solid profit of $1.56 billion last year reinforces its commitment to delivering shareholder value amidst market fluctuations.
“Cardinal Health · expects specialty revenues · to exceed $50 billion · in fiscal 2026”
“Cardinal Health · stock price fell to · $186.14”
“Cardinal Health (CAH) · is currently holding · Zacks Rank #2 · Buy”
“Cardinal Health (CAH) · has a PEG ratio of · 1.24”
“Cardinal Health (CAH) · has a P/CF ratio of · 15.27”
“Cardinal Health (CAH) and The Cooper Companies (COO) · are likely being · undervalued”
“Cardinal Health · reported · free cash flow · US$4.4b”
“Cardinal Health · reported · profit · US$1.56b”
“Cardinal Health · is expanding · its role in the global surgical case carts market · true”
“Cardinal Health · logged a gain · 25.0% over the past year · true”
“Cardinal Health · logged a gain · 126.2% over three years · true”
“Cardinal Health · is dealing with · a US$184m goodwill impairment in the Navista & ION unit · true”